A carregar...
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
BACKGROUND/AIMS: Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with advanced HCC. We retrospectively analyzed a series of Korean patients with...
Na minha lista:
| Publicado no: | Clin Mol Hepatol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The Korean Association for the Study of the Liver
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4612290/ https://ncbi.nlm.nih.gov/pubmed/26527250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2015.21.3.287 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|